Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 46 Records) |
| Query Trace: Leukemia and CYP3A5[original query] |
|---|
| Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013 Feb 98 (2): 193-200. Angelini Sabrina, Soverini Simona, Ravegnini Gloria, Barnett Matt, Turrini Eleonora, Thornquist Mark, Pane Fabrizio, Hughes Timothy P, White Deborah L, Radich Jerald, Kim Dong Wook, Saglio Giuseppe, Cilloni Daniela, Iacobucci Ilaria, Perini Giovanni, Woodman Richard, Cantelli-Forti Giorgio, Baccarani Michele, Hrelia Patrizia, Martinelli Giovan |
| Association of CYP3A5*3 polymorphism with development of acute leukemia. Indian journal of human genetics 2011 Sep 17 (3): 175-8. Rao D Nageswara, Manjula G, Sailaja K, Surekha D, Raghunadharao D, Rajappa Senthil, Vishnupriya |
| SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PloS one 2012 7 (12): 12. Singh O, Chan JY, Lin K, Heng CC, Chowbay B |
| Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Mar 24 (3): 756-60. Seong S J, Lim M, Sohn S K, Moon J H, Oh S-J, Kim B S, Ryoo H M, Chung J S, Joo Y D, Bang S M, Jung C W, Kim D H, Park S Y, Yoon S S, Kim I, Lee H G, Won J H, Min Y H, Cheong J W, Park J S, Eom K S, Hyun M S, Kim M K, Kim H, Park M R, Park J, Kim C S, Kim H J, Kim Y K, Park E K, Zang D Y, Jo D Y, Lee H W, Yoon Y |
| Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PloS one 2012 7 (9): 9. Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y, Han BD, Choi JY, Kim CW, Lee JW, Park KD, Shin HY, Ahn HS |
| CYP3A5 and NAT2 gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment outcome. Molecular and cellular biochemistry 2012 May 364 (1-2): 217-23. Silveira Vanessa S, Canalle Renata, Scrideli Carlos Alberto, Queiroz Rosane G P, Lopes Luiz Fernando, Tone Luiz Gonza |
| CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013 Aug 34 (4): 2357-66. Wang Bao-Sheng, Liu Zhen, Xu Wei-Xue, Sun Shao-Lo |
| Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? Hematology (Amsterdam, Netherlands) 2013 Jan . Bedewy AM, El-Maghraby SM |
| Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 2014 Jun 15 (8): 1105-16. Ceppi Francesco, Langlois-Pelletier Chloé, Gagné Vincent, Rousseau Julie, Ciolino Claire, De Lorenzo Samanta, Kevin Kojok M, Cijov Diana, Sallan Stephen E, Silverman Lewis B, Neuberg Donna, Kutok Jeffery L, Sinnett Daniel, Laverdière Caroline, Krajinovic Ma |
| In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia. The pharmacogenomics journal 2015 Jun 15 (3): 241-7. Gézsi A, Lautner-Csorba O, Erdélyi D J, Hullám G, Antal P, Semsei Á F, Kutszegi N, Hegyi M, Csordás K, Kovács G, Szalai |
| Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. European journal of pharmacology 2015 Aug 765 124-130. Vaidya Shantashri, Ghosh Kanjaksha, Shanmukhaiah Chandrakala, Vundinti Babu R |
| Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia. PloS one 2015 10 (5): e0127308. Lopes Bruno Almeida, Emerenciano Mariana, Gonçalves Bruno Alves Aguiar, Vieira Tállita Meciany, Rossini Ana, Pombo-de-Oliveira Maria |
| CYP3A5 * 3 genetic polymorphism is associated with childhood acute lymphoblastic leukemia risk: A meta-analysis. Biomedical journal 2015 Feb . Ma Li-Min, Liu Hong-Chao, Ruan Lin-Hai, Feng Yan-Mi |
| Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population. Journal of pediatric hematology/oncology 2017 Jul . Kayilio?lu Hülya, Kocak Ulker, Kan Karaer Derya, Percin Emriye F, Sal Ertan, Tekkesin Funda, Isik Melek, Oner Nergiz, Belen Fatma B, Yilmaz Keskin Ebru, Okur Arzu, Albayrak Meryem, Kaya Zuhre, Pinarli Faruk G, Yenicesu Idil, Karadeniz Ceyda, Oguz Aynur, Gursel Turk |
| Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy? Leukemia & lymphoma 2017 09 58 (9): 1-9. Harivenkatesh Natarajan, Kumar Lalit, Bakhshi Sameer, Sharma Atul, Kabra Madhulika, Velpandian Thirumurthy, Gogia Ajay, Shastri Shivaram S, Gupta Yogendra Kum |
| Association of CYP3A5*3 and CYP1A1*2C Polymorphism with Development of Acute Myeloid Leukemia in Egyptian Patients Asian Pacific journal of cancer prevention : APJCP 2017 03 18 (3): 747-752. Abd El Wahab Nahed, Shafik Nevine F, Shafik Roxan E, Taha Sherin A, Shafik Hanan E, Darwish Amira |
| Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia. Molecular medicine reports 2017 Apr . Huang Zhen, Wang Juxiang, Qian Jiangchao, Li Yuan, Xu Zhisheng, Chen Min, Tong Hongf |
| Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. Pharmacological research 2017 Mar . Harivenkatesh Natarajan, Kumar Lalit, Bakhshi Sameer, Sharma Atul, Kabra Madhulika, Velpandian Tirumurthy, Gogia Ajay, Shastri Shivaram S, Biswas Nihar Ranjan, Gupta Yogendra Kum |
| Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenetics and genomics 2018 Aug . Zgheib Nathalie K, Ghanem Khaled M, Tamim Hani, Aridi Carole, Shahine Randa, Tarek Nidale, Saab Raya, Abboud Miguel R, El-Solh Hassan, Muwakkit Samar |
| Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. BMC cancer 2018 Jul 18 (1): 704. Sági Judit C, Egyed Bálint, Kelemen Andrea, Kutszegi Nóra, Hegyi Márta, Gézsi András, Herlitschke Martina Ayaka, Rzepiel Andrea, Fodor Lili E, Ottóffy Gábor, Kovács Gábor T, Erdélyi Dániel J, Szalai Csaba, Semsei Ágnes |
| Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients? Leukemia & lymphoma 2018 May 1-6. Adehin Ayorinde, Adeagbo Babatunde A, Kennedy Martin A, Bolaji Oluseye O, Olugbade Tiwalade A, Bolarinwa Rahman A, Durosinmi Muheez |
| Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. Pharmacological research 2018 Feb . Cargnin Sarah, Ravegnini Gloria, Soverini Simona, Angelini Sabrina, Terrazzino Salvato |
| [Relation between single Nucleotide Polymorphisms of CYP3A5 Gene and MDR1 Gene Loci and Risk of CML Cytogenetic Relapse]. Zhongguo shi yan xue ye xue za zhi 2018 Dec 26 (6): 1644-1648. Yang Zhang-Yuan, Zhang You-Shan, Liang Cai-Xia, Zhou Zheng- |
| The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. Archives of medical science : AMS 2018 Oct 14 (6): 1416-1423. Belohlavkova Petra, Vrbacky Filip, Voglova Jaroslava, Racil Zdenek, Zackova Daniela, Hrochova Katerina, Malakova Jana, Mayer Jiri, Zak Pav |
| Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine-N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients. Frontiers in oncology 2020 9 10 1348. Omran Mervat M, Abdelfattah Raafat, Moussa Heba S, Alieldin Nelly, Shouman Samia |
| Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K? inhibitor therapy. Blood 2020 12 137 (20): 2817-2826. Mato Anthony R, Ghosh Nilanjan, Schuster Stephen J, Lamanna Nicole, Pagel John M, Flinn Ian W, Barrientos Jacqueline C, Rai Kanti R, Reeves James A, Cheson Bruce D, Barr Paul M, Kambhampati Suman, Lansigan Frederick, Pu Jeffrey J, Skarbnik Alan P, Roeker Lindsey, Fonseca Gustavo A, Sitlinger Andrea, Hamadeh Issam S, Dorsey Colleen, LaRatta Nicole, Weissbrot Hanna, Luning Prak Eline T, Tsao Patricia, Paskalis Dana, Sportelli Peter, Miskin Hari P, Weiss Michael S, Svoboda Jakub, Brander Danielle |
| [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2020 11 38 (1): 34-41. He Ying, Zao Xiumei, Wei Xueh |
| Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. International journal of hematology 2020 Jan . Sawaki Akihiko, Miyazaki Kana, Yamaguchi Motoko, Takeuchi Toshifumi, Kobayashi Kyoko, Imai Hiroshi, Tawara Isao, Ono Ryoichi, Nosaka Tetsuya, Katayama Naoyu |
| Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation. Cancer chemotherapy and pharmacology 2023 8 . Shiyu He, Qianhang Shao, Jinxia Zhao, Jialu Bian, Yinyu Zhao, Xu Hao, Yuanyuan Li, Lei Hu, Boyu Liu, Huan He, Lin Huang, Qian Jia |
| Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study. JCO precision oncology 2023 3 7 e2200580. Larkin Trisha, Kashif Reema, Elsayed Abdelrahman H, Greer Beate, Mangrola Karna, Raffiee Roya, Nguyen Nam, Shastri Vivek, Horn Biljana, Lamba Jatinder |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 18, 2023
- Content source: